<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106765</url>
  </required_header>
  <id_info>
    <org_study_id>evoLGI1</org_study_id>
    <nct_id>NCT04106765</nct_id>
  </id_info>
  <brief_title>LGI1-antibody Patients Follow-up</brief_title>
  <acronym>evoLGI1</acronym>
  <official_title>Clinical, EEG and Radiological Initial and Evolutive Characterisation of LGI1-antibody Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune encephalitis involve autoantibodies targeting central nervous system, and
      particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is
      revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial
      dystonic or generalized seizures, and cognitive disorders.

      This disease is rare and its clinical, EEG and radiological characterisation is not
      sufficiently established. The investigators will evaluate these three aspects for the
      anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of epileptic seizures</measure>
    <time_frame>12 MONTHS</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Anti-LGI1 Encephalitis</condition>
  <arm_group>
    <arm_group_label>: epileptic LGI1-antibody patients</arm_group_label>
    <description>Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom
Evaluated items:
Number of seizures
Type of seizures
Presence of EEG abnormalities
Presence of IRM abnormalities
Time before cognitive disorders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cognitive LGI1-antibody patients</arm_group_label>
    <description>Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom
Evaluated items:
Presence of EEG abnormalities
Presence of IRM abnormalities
Time before epileptic seizures</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study Population Description : Adult patients presenting an anti-LGI1 autoimmune
        encephalitis, followed in France and diagnosed by sera or CSF samples at the National
        Reference Center of autoimmune encephalitis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National
             Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.

          -  Clinical follow-up in France

        Exclusion Criteria:

          -  Anti-LGI1 antibody associated with another encephalitis antibody

          -  Foreign follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome HONNORAT, pHd</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Reference Center of autoimmune encephalitis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerome HONNORAT, PhD</last_name>
    <phone>4 72 35 78 08</phone>
    <phone_ext>33</phone_ext>
    <email>jerome.honnorat@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Géraldine PICARD</last_name>
    <phone>4 72 35 58 42</phone>
    <phone_ext>33</phone_ext>
    <email>geraldine.picard@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jerome HONNORAT, PhD</last_name>
      <phone>4 72 35 78 08</phone>
      <phone_ext>33</phone_ext>
      <email>jerome.honnorat@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

